Agenus (NASDAQ: [[ticker:AGEN]]) has appointed Jean-Marie Cuillerot as its vice president and global head of clinical development. The Lexington, MA-based immuno-oncology company’s drug pipeline includes potential therapies for cancer, as well as shingles and malaria. Cuillerot’s cancer drug development experience includes posts at EMD Serono Research and Development Institute, Merck Serono, and Bristol-Myers Squibb (NYSE: [[ticker:BMY]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
